Correct, the old formulation can only be used as central line so practically limited to liquid tumors. Lederle couldn't develop the current peripheral line RC220 version with 10years of development.
The RC220 patents include a unique reformulation process so can't bypass without infringing. Difficult to see how someone would run the risk, instead its more likely they would just buyout Race and provide certainty without the hassle.
Cardioprotection thread, page-719
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |